3+ day, 17+ hour ago  (424+ words) The agency's decision to hold an advisory committee meeting on the topic comes after HHS Secretary Robert F. Kennedy Jr. told podcaster Joe Rogan he's a "big fan" of peptides. The proposed peptide reclassification is the latest move by Health and…...

3+ day, 54+ min ago  (657+ words) Some 1, 390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using Open AI's "GPT-Rosalind" and Janux debuted a "double-masked" T cell engager. Don't miss tomorrow's biopharma industry news Lilly's obesity pill off to a strong…...

4+ day, 16+ hour ago  (245+ words) Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases. Beeline Medicines emerged from stealth Wednesday with plans to develop "precision therapies" for immune diseases, nearly a year…...

4+ day, 17+ hour ago  (357+ words) The California biotech has one therapy in Phase 1 testing and expects another to advance to the clinic later this year. Terremoto, whose name translates to "earthquake," trumpets that its science offers a "seismic shift'in drug discovery and development. The company's…...

2+ week, 5+ day ago  (349+ words) In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets. Merck and Co. has signed an agreement with California-based Infinimmune to develop multiple antibodies for various disease…...

5+ day, 20+ hour ago  (701+ words) Novo intends to "fully integrate" AI capabilities across its operations. Elsewhere, Regeneron made its first foray into radiopharmaceuticals and a GSK cancer drug showed early promise. Don't miss tomorrow's biopharma industry news Novo teams with Open AI; Ideaya gets muted…...

5+ day, 23+ hour ago  (338+ words) The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity believed to be worth more than $1 billion annually. Filspari has undergone an unusual regulatory journey on its way to an…...

1+ week, 3+ day ago  (253+ words) After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead. Lilly is looking to repeat its success in the injectable GLP-1 market, where it…...

2+ week, 3+ day ago  (797+ words) Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio's cell therapy hit a delay and Korsana entered a reverse merger. Don't miss tomorrow's biopharma industry news Immunovant eye drug flunks Phase 3 studies;…...

1+ week, 6+ day ago  (581+ words) The findings could help Amgen defend Tepezza's market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing. Amgen said an injectable version of its blockbuster eye disease drug Tepezza hit both goals in a key late-stage…...